Fuji Keizai Estimates Japan’s Generic Drug Market To Grow 17.5 percent In 2010
This article was originally published in PharmAsia News
Executive Summary
Tokyo based market research company Fuji Keizai estimated the generic drug market in Japan will grow by 17.5 percent to ¥359.7 billion in 2010. Generic drugs will account for 5.2 percent of the prescription drug market. Reasons cited by the company include increased promotion in generic drug prescriptions among national hospitals, implementation of a diagnostic procedure combined payment system and the change in prescription forms. Fuji further noted that due to the expansion of DPC system, the use of generic injection products are increasing and the upward trend will continue. In terms of drug categories, Fuji estimates that hypertension, schizophrenia and diabetic drugs are among the generics that will grow the fastest. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.